Variables | Univariate analysis | Multivariate analysis | ||
---|---|---|---|---|
HR(95%CI) | P | HR(95%CI) | P | |
Age | ||||
< =50 | 1 | 1 | ||
50–60 | 1.13 (0.89–1.44) | 0.301 | 1.10 (0.86–1.40) | 0.445 |
> 60 | 2.25 (1.86–2.74) | < 0.001 | 2.11 (1.72–2.60) | < 0.001 |
Race | ||||
White | 1 | 1 | ||
African American | 1.51 (1.26–1.80) | < 0.001 | 1.05 (0.87–1.27) | 0.576 |
Others | 0.43 (0.24–0.77) | 0.004 | 0.48 (0.27–0.85) | 0.012 |
Unknown | 0.53 (0.24–1.19) | 0.126 | 0.49 (0.22–1.10) | 0.082 |
Comorbidity score | ||||
Score 0 | 1 | 1 | ||
Score 1 | 2.17 (1.85–2.54) | < 0.001 | 1.65 (1.40–1.95) | < 0.001 |
Grade | ||||
I | 1 | 1 | ||
II | 1.20 (0.94–1.54) | 0.149 | 0.98 (0.76–1.26) | 0.877 |
III | 2.05 (1.62–2.58) | < 0.001 | 1.35 (1.05–1.74) | 0.02 |
Unknown/IV | 1.86 (1.39–2.49) | < 0.001 | 1.05 (0.77–1.42) | 0.767 |
T-stage | ||||
T0-T1 | 1 | 1 | ||
T2 | 2.24 (1.86–2.69) | < 0.001 | 1.65 (1.35–2.03) | < 0.001 |
T3–4 | 5.63 (4.60–6.90) | < 0.001 | 2.75 (2.14–3.55) | < 0.001 |
Tx | 1.25 (1.04–1.51) | 0.017 | 0.62 (0.45–0.85) | 0.003 |
N-stage | ||||
N0 | 1 | 1 | ||
N1 | 1.82 (1.49–2.22) | < 0.001 | 1.77 (1.43–2.18) | < 0.001 |
N2–3 | 3.61 (2.90–4.49) | < 0.001 | 2.18 (1.69–2.83) | < 0.001 |
Nx | 1.12 (0.94–1.32) | 0.197 | 0.95 (0.70–1.30) | 0.764 |
M-stage | ||||
M0 | 1 | 1 | ||
M1 | 8.47 (6.42–11.17) | < 0.001 | 4.50 (3.29–6.16) | < 0.001 |
Mx | 2.04 (1.74–2.39) | < 0.001 | 1.90 (1.53–2.36) | < 0.001 |
Histology | ||||
Infiltrating Ductal Carcinoma | 1 | 1 | ||
Squamous Cell Carcinoma | 2.39 (2.06–2.77) | < 0.001 | 1.37 (1.15–1.64) | < 0.001 |
Lymphovascular invasiona | ||||
Absence | 1 | Not included | ||
Presence | 1.91 (1.37–2.67) | < 0.001 | ||
Not applicable/Unknown | 2.18 (1.63–2.91) | < 0.001 | ||
Estrogen Receptor | ||||
Negative | 1 | 1 | ||
Positive | 0.53 (0.46–0.61) | < 0.001 | 0.86 (0.67–1.10) | 0.218 |
Unknown | 0.85 (0.67–1.08) | 0.195 | 2.46 (0.60–10.15) | 0.212 |
Progesterone Receptor | ||||
Negative | 1 | 1 | ||
Positive | 0.56 (0.48–0.65) | < 0.001 | 0.96 (0.76–1.20) | 0.724 |
Unknown | 0.92 (0.73–1.16) | 0.484 | 0.31 (0.08–1.27) | 0.103 |
HER2a | ||||
Negative | 1 | Not included | ||
Positive | 0.83 (0.57–1.22) | 0.347 | ||
Borderline/Unknown | 1.20 (0.87–1.66) | 0.266 | ||
Surgery | ||||
Breast-conserving surgery | 1 | 1 | ||
Mastectomy | 2.22 (1.90–2.59) | < 0.001 | 1.26 (1.04–1.54) | 0.02 |
Others/Unknown | 7.05 (5.77–8.62) | < 0.001 | 6.57 (5.04–8.55) | < 0.001 |
Radiation therapy | ||||
No | 1 | 1 | ||
Yes | 0.54 (0.47–0.62) | < 0.001 | 0.92 (0.77–1.10) | 0.351 |
Unknown | 0.50 (0.24–1.05) | 0.067 | 0.54 (0.25–1.17) | 0.12 |
Chemotherapy | ||||
No | 1 | 1 | ||
Yes | 0.89 (0.77–1.03) | 0.116 | 0.67 (0.55–0.80) | < 0.001 |
Unknown | 0.72 (0.53–0.99) | 0.043 | 0.61 (0.43–0.85) | 0.004 |
Endocrine therapy | ||||
No | 1 | 1 | ||
Yes | 0.44 (0.38–0.51) | < 0.001 | 0.60 (0.50–0.73) | < 0.001 |
Unknown | 0.56 (0.40–0.78) | < 0.001 | 0.77 (0.54–1.09) | 0.145 |